JP2024107295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024107295A5 JP2024107295A5 JP2024094278A JP2024094278A JP2024107295A5 JP 2024107295 A5 JP2024107295 A5 JP 2024107295A5 JP 2024094278 A JP2024094278 A JP 2024094278A JP 2024094278 A JP2024094278 A JP 2024094278A JP 2024107295 A5 JP2024107295 A5 JP 2024107295A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sirna
- nucleotide sequence
- cell line
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833548P | 2019-04-12 | 2019-04-12 | |
| US62/833,548 | 2019-04-12 | ||
| US201962839207P | 2019-04-26 | 2019-04-26 | |
| US62/839,207 | 2019-04-26 | ||
| US202062979483P | 2020-02-21 | 2020-02-21 | |
| US62/979,483 | 2020-02-21 | ||
| JP2021559793A JP7560475B2 (ja) | 2019-04-12 | 2020-04-09 | 操作された産生細胞株ならびにそれを作製および使用する方法 |
| PCT/US2020/027489 WO2020210507A1 (en) | 2019-04-12 | 2020-04-09 | Engineered producer cell lines and methods of making and using the same |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559793A Division JP7560475B2 (ja) | 2019-04-12 | 2020-04-09 | 操作された産生細胞株ならびにそれを作製および使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024107295A JP2024107295A (ja) | 2024-08-08 |
| JP2024107295A5 true JP2024107295A5 (enExample) | 2024-11-14 |
| JP7706607B2 JP7706607B2 (ja) | 2025-07-11 |
Family
ID=70465550
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559793A Active JP7560475B2 (ja) | 2019-04-12 | 2020-04-09 | 操作された産生細胞株ならびにそれを作製および使用する方法 |
| JP2024094278A Active JP7706607B2 (ja) | 2019-04-12 | 2024-06-11 | 操作された産生細胞株ならびにそれを作製および使用する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559793A Active JP7560475B2 (ja) | 2019-04-12 | 2020-04-09 | 操作された産生細胞株ならびにそれを作製および使用する方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12018288B2 (enExample) |
| EP (2) | EP4603579A3 (enExample) |
| JP (2) | JP7560475B2 (enExample) |
| KR (1) | KR20210152514A (enExample) |
| CN (1) | CN113966395B (enExample) |
| AU (1) | AU2020270960B2 (enExample) |
| BR (1) | BR112021020391A2 (enExample) |
| CA (1) | CA3136246A1 (enExample) |
| CO (1) | CO2021013699A2 (enExample) |
| IL (1) | IL287106A (enExample) |
| MX (1) | MX2021012489A (enExample) |
| PH (1) | PH12021552577A1 (enExample) |
| SG (1) | SG11202110904PA (enExample) |
| TW (1) | TWI859216B (enExample) |
| WO (1) | WO2020210507A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023536148A (ja) | 2020-07-30 | 2023-08-23 | シェイプ セラピューティクス インク． | Ｒａａｖウイルス粒子の誘導産生のための安定な細胞株 |
| JP2024531138A (ja) | 2021-08-11 | 2024-08-29 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | 筋ジストロフィーを処置するための組成物および方法 |
| JP2024537896A (ja) | 2021-10-18 | 2024-10-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞 |
| WO2023077078A1 (en) | 2021-10-29 | 2023-05-04 | Ultragenyx Pharmaceutical Inc. | Engineered cell lines for increased production of recombinant adeno-associated virus (raav) |
| EP4490278A1 (en) | 2022-03-07 | 2025-01-15 | Ultragenyx Pharmaceutical Inc. | Modified batch aav production systems and methods |
| WO2025078616A1 (en) * | 2023-10-12 | 2025-04-17 | Cevec Pharmaceuticals Gmbh | Cellular factors affecting recombinant aav production |
| WO2025226558A1 (en) | 2024-04-22 | 2025-10-30 | Ultragenyx Pharmaceutical Inc. | Multi-step filtration and clarification methods for recombinant adeno-associated virus purification |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5387484A (en) | 1992-07-07 | 1995-02-07 | International Business Machines Corporation | Two-sided mask for patterning of materials with electromagnetic radiation |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| EP0796339A1 (en) | 1994-12-06 | 1997-09-24 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
| US5741683A (en) | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| US5688676A (en) | 1995-06-07 | 1997-11-18 | Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| WO1998027204A2 (en) | 1996-12-18 | 1998-06-25 | Targeted Genetics Corporation | Aav split-packaging genes and cell lines comprising such genes for use in the production of recombinant aav vectors |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| WO1999011764A2 (en) * | 1997-09-05 | 1999-03-11 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of recombinant aav vectors |
| JP2002528087A (ja) | 1998-10-27 | 2002-09-03 | クルセル ホランド ベー ヴェー | 改良ａａｖベクター産生 |
| DE19905501B4 (de) | 1999-02-10 | 2005-05-19 | MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie | Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels |
| US7510872B2 (en) | 2003-02-26 | 2009-03-31 | Nationwide Children's Hospital | Recombinant adeno-associated virus production |
| EP1888783B1 (en) | 2005-05-27 | 2011-10-26 | EVOTEC Neurosciences GmbH | Kcnn3 as diagnostic and therapeutic target for alzheimer's disease |
| EP2311967B1 (en) | 2005-10-20 | 2017-09-20 | UniQure IP B.V. | Improved AAV vectors produced in insect cells |
| US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| RU2015137703A (ru) | 2013-02-05 | 2017-03-09 | Юниверсити Оф Джорджиа Рисерч Фаундейшн, Инк. | Линии клеток для получения вирусов и способы их применения |
| CN104592364B (zh) * | 2013-10-30 | 2018-05-01 | 北京大学 | 定点突变和定点修饰的腺相关病毒、其制备方法及应用 |
| GB201401707D0 (en) | 2014-01-31 | 2014-03-19 | Sec Dep For Health The | Adeno-associated viral vectors |
| US20160319277A1 (en) | 2015-01-28 | 2016-11-03 | The Johns Hopkins University | METHODS OF IMPROVED PROTEIN PRODUCTION USING MIRNAs AND SIRNAs |
| ES2938833T3 (es) | 2016-03-28 | 2023-04-17 | Ultragenyx Pharmaceutical Inc | Métodos de inactivación térmica de adenovirus |
| US20190290710A1 (en) | 2016-07-12 | 2019-09-26 | Dimension Therapeutics, Inc. | Use of glucocorticoid analogs to enhance recombinant adeno-associated virus yield |
| ES3012649T3 (en) | 2016-10-14 | 2025-04-09 | Ultragenyx Pharmaceutical Inc | Use of tonicifying agents to enhance recombinant adeno-associated virus yield |
| EP3601581B1 (en) | 2017-03-22 | 2025-04-30 | Ultragenyx Pharmaceutical Inc. | CELL CULTURE METHODS INVOLVING HDAC INHIBITORS OR REP PROTEINS |
| WO2018175773A1 (en) | 2017-03-22 | 2018-09-27 | Dimension Therapeutics | Methods for enhancing yield of recombinant adeno-associated virus |
| US12487152B2 (en) | 2017-05-09 | 2025-12-02 | Ultragenyx Pharmaceutical Inc. | Scalable method for producing transfection reagents |
| US20200340013A1 (en) | 2018-01-19 | 2020-10-29 | The University Of North Carolina At Chapel Hill | Methods and compositions for inhibition of innate immune response associated with aav transduction |
| US12577539B2 (en) | 2019-04-26 | 2026-03-17 | The Regents Of The University Of California | Cells for enhanced production of adeno-associated virus |
| WO2023077078A1 (en) * | 2021-10-29 | 2023-05-04 | Ultragenyx Pharmaceutical Inc. | Engineered cell lines for increased production of recombinant adeno-associated virus (raav) |
-
2020
- 2020-04-09 EP EP25183274.7A patent/EP4603579A3/en active Pending
- 2020-04-09 JP JP2021559793A patent/JP7560475B2/ja active Active
- 2020-04-09 PH PH1/2021/552577A patent/PH12021552577A1/en unknown
- 2020-04-09 CN CN202080028310.8A patent/CN113966395B/zh active Active
- 2020-04-09 EP EP20722185.4A patent/EP3953458A1/en active Pending
- 2020-04-09 KR KR1020217036581A patent/KR20210152514A/ko active Pending
- 2020-04-09 WO PCT/US2020/027489 patent/WO2020210507A1/en not_active Ceased
- 2020-04-09 BR BR112021020391A patent/BR112021020391A2/pt unknown
- 2020-04-09 CA CA3136246A patent/CA3136246A1/en active Pending
- 2020-04-09 MX MX2021012489A patent/MX2021012489A/es unknown
- 2020-04-09 SG SG11202110904PA patent/SG11202110904PA/en unknown
- 2020-04-09 AU AU2020270960A patent/AU2020270960B2/en active Active
- 2020-04-09 US US16/844,475 patent/US12018288B2/en active Active
- 2020-04-10 TW TW109112259A patent/TWI859216B/zh active
-
2021
- 2021-10-07 IL IL287106A patent/IL287106A/en unknown
- 2021-10-14 CO CONC2021/0013699A patent/CO2021013699A2/es unknown
-
2024
- 2024-05-09 US US18/659,358 patent/US20240376440A1/en active Pending
- 2024-06-11 JP JP2024094278A patent/JP7706607B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024107295A5 (enExample) | ||
| Kaur et al. | Thermodynamic, counterion, and hydration effects for the incorporation of locked nucleic acid nucleotides into DNA duplexes | |
| Montiel-Gonzalez et al. | Current strategies for site-directed RNA editing using ADARs | |
| Devi | siRNA-based approaches in cancer therapy | |
| CN116194582A (zh) | 一种改善的rna编辑方法 | |
| US20180127754A1 (en) | Bivalent antisense oligonucleotides | |
| JP2010509923A (ja) | 標的ｒｎａの活性を変化させるためのオリゴヌクレオチド | |
| Xie et al. | Adeno-associated virus-mediated microRNA delivery and therapeutics | |
| JP2005501557A5 (enExample) | ||
| Herrera-Carrillo et al. | CRISPR therapy towards an HIV cure | |
| US20240401043A1 (en) | Programmable conditional sirnas and uses thereof | |
| KR101324390B1 (ko) | 단일 또는 멀티 표적 유전자를 억제하는 멀티-시스트로닉 ｓｈＲＮＡ 발현 카세트 | |
| RU2013139298A (ru) | Способ конструирования специфичных промоторов | |
| Ui-Tei | Optimal choice of functional and off-target effect-reduced siRNAs for RNAi therapeutics | |
| Ng et al. | Folding double‐stranded DNA into designed shapes with triplex‐forming oligonucleotides | |
| Chuang et al. | Methods for in vitro CRISPR/CasRx-mediated RNA editing | |
| EP2643341A1 (en) | Oligonucleotides for modulation of target rna activity | |
| US20100144831A1 (en) | Blocking of gene expression in eukaryotic cells | |
| Garcia-Guerra et al. | Tissue-specific modulation of CRISPR activity by miRNA-sensing guide RNAs | |
| Ill et al. | Gene therapy progress and prospects: recent progress in transgene and RNAi expression cassettes | |
| WO2024163839A1 (en) | Methods and compositions for modulating splicing | |
| WO2021136520A1 (zh) | 一种靶向编辑rna的新方法 | |
| CN104031916B (zh) | 新型RNAi前体及其制备和应用 | |
| CN101402945A (zh) | 表达抗传染性法氏囊病病毒微小rna重组禽腺联病毒的制备方法 | |
| CN117396605A (zh) | 改进的嵌合和工程化支架以及多重化抑制性rna簇 |